Recent Clinical Data for Dubodencel (DOC1021) in Glioblastoma Drive Financing with Backing from

最近，Dubodencel（DOC1021）在胶质母细胞瘤中的临床数据推动了融资，并获得了支持。

Baylor College of Medicine

贝勒医学院

and The Brain Tumor Investment Fund

和脑肿瘤投资基金

HOUSTON

休斯顿

,

，

May 30, 2025

2025年5月30日

/PRNewswire/ --

/PRNewswire/ --

Diakonos Oncology Corp.,

执事肿瘤学公司，

a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced the closing of a

一家临床阶段的生物技术公司，致力于开发新一代免疫疗法以治疗棘手且侵袭性的癌症，今天宣布了一项交易的完成。

$20 million

2000万美元

private placement of Simple Agreements for Future Equity (SAFE) to accelerate the company's Phase 2 glioblastoma trial for dubodencel, also known as DOC1021, and support the expansion of its clinical portfolio to other indications, including refractory melanoma. The financing includes backing by new investors .

未来股权简单协议（SAFE）的私募融资，以加速公司第二阶段胶质母细胞瘤试验药物dubodencel（也称为DOC1021）的研发，并支持其临床产品组合扩展到其他适应症，包括难治性黑色素瘤。此次融资得到了新投资者的支持。

Baylor College of Medicine

贝勒医学院

(BCM), the Brain Tumor Investment Fund (BTIF), and the Buttonwood Titan QC Fund, with additional participation from existing shareholders including CEO

(BCM)、脑肿瘤投资基金（BTIF）和Buttonwood Titan QC基金，现有股东也参与其中，包括首席执行官。

Mike Wicks

迈克·威克斯

, MS. BCM is also contributing in-kind services toward the company's pre-clinical and clinical development programs. This

，贝勒医学院（BCM）还为公司的临床前和临床开发计划提供实物服务。这

$20 million

2000万美元

financing follows Diakonos' oversubscribed

融资跟随Diakonos的超额认购

$11.4 million

1140万美元

seed financing that closed last year and serves as a bridge to a Series A financing that the company plans to launch in the second half of this year.

去年完成的种子轮融资，作为公司计划在今年下半年启动的A轮融资的桥梁。

'With our Phase 2 glioblastoma trial underway at leading treatment centers across the U.S., the financing comes at a critical inflection point as we begin defining the path toward commercialization,' said

“随着我们第二阶段胶质母细胞瘤试验在美国各地的主要治疗中心进行，这笔融资来得正是时候，因为我们开始明确通往商业化的道路，”

Jay Hartenbach

杰伊·哈滕巴赫

, President and Chief Operating Officer of Diakonos Oncology. 'Early clinical results in both glioblastoma and pancreatic cancer continue to exceed expectations, and when viewed alongside our data from a range of preclinical models, we are increasingly optimistic that this patient-derived immunotherapy holds potential for additional indications with high unmet need.'.

迪亚科诺斯肿瘤学公司总裁兼首席运营官表示：“胶质母细胞瘤和胰腺癌的早期临床结果继续超出预期，结合我们从一系列临床前模型中获得的数据，我们越来越乐观地认为，这种患者来源的免疫疗法在其他具有高度未满足需求的适应症上也具有潜力。”

John Higgins

约翰·希金斯

, Managing Director at the Brain Tumor Investment Fund, added, 'The promising Phase 1 data for dubodencel in glioblastoma were a strong motivator for us to help fund the Phase 2 trial, and we are pleased that our investment will serve as a catalyst for additional fundraising as the company advances the glioblastoma program and expands its clinical pipeline.'.

“,脑肿瘤投资基金的董事总经理补充说：‘dubodencel在胶质母细胞瘤中的1期数据非常有前景，这成为我们帮助资助2期试验的强大动力。我们很高兴，随着公司推进胶质母细胞瘤项目并扩展其临床管线，我们的投资将成为额外筹款的催化剂。’”

Joseph Petrosino

约瑟夫·彼得罗西诺

, Ph.D., Chief Scientific Innovation Officer of

，博士，首席科学创新官

Baylor College of Medicine

贝勒医学院

, said, 'At BCM, we are eager to propel our latest discoveries to the bedside, particularly for new therapies targeting glioblastoma and pancreatic cancer, where patients are in desperate need for better options. We are proud to work with Diakonos to accelerate these exciting early clinical results, and we are eager to support Diakonos as it builds on encouraging pre-clinical data suggesting dubodencel may be more broadly successful for the treatment of other difficult cancers and diseases.'.

表示：“在BCM，我们渴望将我们最新的发现应用于临床，特别是针对胶质母细胞瘤和胰腺癌的新疗法，这些患者迫切需要更好的选择。我们很自豪能与Diakonos合作，加速这些令人兴奋的早期临床结果，并且我们渴望支持Diakonos，因为它基于令人鼓舞的临床前数据，表明dubodencel可能在治疗其他难治癌症和疾病方面取得更广泛的成功。”

Joseph Gunnar

约瑟夫·贡纳尔

& Co. LLC served as placement agent for Diakonos in the SAFE offering. A SAFE is a non-debt instrument where an investor provides funding and receives the right to convert the investment into equity shares at a later date upon the occurrence of specified events, typically when a company raises a qualified equity financing round or experiences a liquidity event..

& Co. LLC 在 Diakonos 的 SAFE 发行中担任了配售代理。SAFE 是一种非债务工具，投资者提供资金，并在发生特定事件时（通常是在公司进行合格的股权融资或经历流动性事件时）获得将投资转换为股权的权利。

About Dubodencel

关于杜博登塞尔

Dubodencel, also known as DOC1021, is a first-in-class, double-loaded autologous dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens..

Dubodencel，又称DOC1021，是一种首创的、双负载的自体树突细胞疗法，独特地结合了肿瘤裂解物和扩增的肿瘤来源mRNA。这种免疫疗法利用患者的树突细胞与从新鲜获取的患者肿瘤样本中制备的mRNA和蛋白质相结合。

The unique double loading approach, which mimics a viral infection, unlocks a synergistic and exponentially more powerful tumor killing T

独特的双重加载方法模仿病毒感染，解锁了协同作用且更强大的肿瘤杀伤T细胞。

H

H

1 response driven by dual protein and RNA antigen sourcing, and it allows targeting of the complete cancer antigen pool. Moreover, the approach does not require any molecular modification of the patient's immune cells for manufacturing, and it does not require preconditioning of bone marrow or high dose IL-2 for administration.

该方法由双重蛋白和RNA抗原驱动，并能够靶向完整的肿瘤抗原库。此外，这种方法不需要对患者的免疫细胞进行任何分子修饰，也不需要为进行治疗而预先处理骨髓或使用高剂量IL-2。

Dubodencel allows for a simple administration in the outpatient setting and broad reach via community cancer centers..

杜博登塞尔允许在门诊环境中简单施用，并通过社区癌症中心广泛覆盖。

In addition to the recently opened Phase 2 glioblastoma study, a clinical trial of Diakonos' dubodencel is ongoing for the treatment of pancreatic cancer. Diakonos received Fast Track designations from the FDA for both the glioblastoma and pancreatic cancer programs in

除了最近开展的第二阶段胶质母细胞瘤研究外，Diakonos的dubodencel治疗胰腺癌的临床试验正在进行中。Diakonos已获得FDA对胶质母细胞瘤和胰腺癌项目的快速通道资格。

October 2023

2023年10月

and

和

May 2024

2024年5月

, respectively. The company received Orphan Drug Designation for the glioblastoma program in

，分别。该公司获得了胶质母细胞瘤项目的孤儿药资格认定在

January 2024

2024年1月

.

。

About Diakonos Oncology Corp.

关于Diakonos肿瘤学公司

Based in

总部位于

Houston

休斯顿

, Diakonos Oncology Corp. is a clinical-stage biotechnology company dedicated to revolutionizing cancer immunotherapy with its proprietary double-loaded, patient-derived dendritic cell therapeutic platform focused on addressing the critical, unmet medical need for treatment of late-state and aggressive cancers.

迪亚科诺斯肿瘤公司是一家临床阶段的生物技术公司，致力于通过其专有的双载荷、患者来源的树突细胞治疗平台彻底改变癌症免疫疗法，专注于满足晚期和侵袭性癌症治疗中未被满足的关键医疗需求。

For more information visit: .

更多信息请访问：。

https://www.diakonosoncology.com

https://www.diakonosoncology.com

About

关于

Baylor College of Medicine

贝勒医学院

Baylor College of Medicine

贝勒医学院

in

在

Houston

休斯顿

is recognized as a health sciences university and is known for excellence in education, research and patient care. Baylor is a top-ranked medical school and listed 20

被公认为是一所健康科学大学，以卓越的教育、研究和患者护理而闻名。贝勒是一所排名靠前的医学院，位列前20。

th

th

among all U.S. medical schools for National Institutes of Health funding and No. 1 in

在美国所有医学院中，国立卫生研究院资助排名第一，并且在

Texas

德克萨斯州

. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke's Medical Center, part of St. Luke's Health. Currently, Baylor has more than 3,000 trainees in medical, graduate, nurse anesthesia, physician assistant, orthotics and genetic counseling as well as residents and postdoctoral fellows. For more information visit: .

位于德克萨斯医疗中心的贝勒医学院与七家教学医院有合作关系，并且共同拥有和运营贝勒圣卢克医疗中心，该中心是圣卢克健康的一部分。目前，贝勒有超过3000名医学、研究生、麻醉护士、医师助理、矫正术和遗传咨询以及住院医生和博士后研究员的学员。欲了解更多信息，请访问：。

https://www.bcm.edu/

https://www.bcm.edu/

About

关于

The Brain Tumor Investment Fund

脑瘤投资基金

The Brain Tumor Investment Fund is a growing and diverse venture philanthropy fund that leverages the National Brain Tumor Society's (NBTS) 30 years of experience, expertise, and achievement. The fund will support NBTS's vision to conquer and cure brain tumors by investing in biotechnology, pharmaceutical, and medical device companies developing products to improve the lives of brain tumor patients..

脑肿瘤投资基金是一个不断增长且多元化的风险慈善基金，利用了国家脑肿瘤协会 (NBTS) 30 年的经验、专业知识和成就。该基金将通过投资于正在开发改善脑肿瘤患者生活的生物技术、制药和医疗器械公司，来支持 NBTS 征服和治愈脑肿瘤的愿景。

The Brain Tumor Investment Fund sparks private sector investment in brain tumor research and to create a robust and diverse market for drug development, while increasing the likelihood of success for companies bringing life-changing products to market. For more information visit:

脑肿瘤投资基金激发私营部门对脑肿瘤研究的投资，创造一个强大而多样化的药物开发市场，同时增加公司推出改变生命的产品的成功可能性。欲了解更多信息，请访问：

https://braintumorinvestmentfund.org/

https://braintumorinvestmentfund.org/

SOURCE Diakonos Oncology

来源：迪亚科诺斯肿瘤学

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用